Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2118 participants.

Also called NCT01321255

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 2,118 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01321255
  • EudraCT 2010-022492-54
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Argentina, Brazil, Italy, Paraguay, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01321255. Randomized; no masking; primary purpose prevention. Start 2012-01 (registry gives no type); primary completion 2014-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.
Acronym
FOCUS
Intervention (Drug)
FDC
Intervention (Drug)
Separately drugs, simvastatin, aspirin and ramipril
Lead sponsor
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (class: other)
Collaborator
Mario Negri Institute for Pharmacological Research (class: other)
Collaborator
Rusculleda Foundation Instituto DAMIC (class: not stated)
Collaborator
Fundacion Clinic per a la Recerca Biomédica (class: other)
Collaborator
ARTTIC International Management Services (class: not stated)
Collaborator
Federación Argentina de Cardiología FAC (class: not stated)
Collaborator
World Health Organization (class: other)
Collaborator
Instituto de Salud Carlos III (class: other government)
Collaborator
Ferrer Internacional S.A. (class: industry)

Record details

Record id
cardio:ct-nct01321255
Content hash
67c9d6094806a41aad279784568ce2926511bb8c328efc2b12b4129b634e2269